On the public citation graph

A review of treatment modalities for Middle East Respiratory Syndrome

https://doi.org/10.1093/jac/dkw338
0 signed · 236 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.289.21.joc30885openalex-snapshot
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
inferredcites →https://doi.org/10.1001/jama.290.20.2663openalex-snapshot
Temporal Patterns of Hepatic Dysfunction and Disease Severity in Patients With SARS
inferredcites →https://doi.org/10.1001/jama.290.24.3222openalex-snapshot
Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome
inferredcites →https://doi.org/10.1002/hep.21102openalex-snapshot
The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro†
inferredcites →https://doi.org/10.1007/s00134-003-2143-yopenalex-snapshot
Short-term outcome of critically ill patients with severe acute respiratory syndrome
inferredcites →https://doi.org/10.1007/s10096-004-1271-9openalex-snapshot
Use of convalescent plasma therapy in SARS patients in Hong Kong
inferredcites →https://doi.org/10.1016/0092-8674(93)90637-6openalex-snapshot
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
inferredcites →https://doi.org/10.1016/j.antiviral.2006.03.001openalex-snapshot
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
inferredcites →https://doi.org/10.1016/j.antiviral.2006.05.019openalex-snapshot
Coronaviruses and their therapy
inferredcites →https://doi.org/10.1016/j.antiviral.2014.07.014openalex-snapshot
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
inferredcites →https://doi.org/10.1016/j.antiviral.2014.11.010openalex-snapshot
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
inferredcites →https://doi.org/10.1016/j.antiviral.2014.12.011openalex-snapshot
Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
inferredcites →https://doi.org/10.1016/j.bbrc.2004.08.085openalex-snapshot
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
inferredcites →https://doi.org/10.1016/j.bbrc.2004.11.128openalex-snapshot
Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
inferredcites →https://doi.org/10.1016/j.crad.2003.12.008openalex-snapshot
Avascular necrosis of bone in severe acute respiratory syndrome
inferredcites →https://doi.org/10.1016/j.ijantimicag.2014.07.026openalex-snapshot
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
inferredcites →https://doi.org/10.1016/j.ijid.2013.12.003openalex-snapshot
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
inferredcites →https://doi.org/10.1016/j.jcv.2004.03.003openalex-snapshot
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
inferredcites →https://doi.org/10.1016/j.jcv.2004.07.006openalex-snapshot
Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
inferredcites →https://doi.org/10.1016/j.jinf.2013.03.015openalex-snapshot
Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
inferredcites →https://doi.org/10.1016/j.jinf.2013.09.029openalex-snapshot
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
inferredcites →https://doi.org/10.1016/j.jiph.2016.04.001openalex-snapshot
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
inferredcites →https://doi.org/10.1016/j.jiph.2016.04.003openalex-snapshot
Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
inferredcites →https://doi.org/10.1016/j.micinf.2014.11.008openalex-snapshot
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
inferredcites →https://doi.org/10.1016/j.molcel.2005.05.014openalex-snapshot
Cyclophilin B Is a Functional Regulator of Hepatitis C Virus RNA Polymerase
inferredcites →https://doi.org/10.1016/j.virol.2004.08.011openalex-snapshot
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)
inferredcites →https://doi.org/10.1016/j.virol.2014.10.006openalex-snapshot
Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry
inferredcites →https://doi.org/10.1016/j.virol.2016.01.004openalex-snapshot
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
inferredcites →https://doi.org/10.1016/s0140-6736(03)13077-2openalex-snapshot
Coronavirus as a possible cause of severe acute respiratory syndrome
inferredcites →https://doi.org/10.1016/s0140-6736(03)13265-5openalex-snapshot
Development of a standard treatment protocol for severe acute respiratory syndrome
inferredcites →https://doi.org/10.1016/s0140-6736(03)13412-5openalex-snapshot
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
inferredcites →https://doi.org/10.1016/s0140-6736(03)13615-xopenalex-snapshot
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
inferredcites →https://doi.org/10.1016/s0140-6736(03)13973-6openalex-snapshot
Treatment of SARS with human interferons
inferredcites →https://doi.org/10.1016/s1473-3099(11)70065-2openalex-snapshot
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial
inferredcites →https://doi.org/10.1016/s1473-3099(14)70717-0openalex-snapshot
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
inferredcites →https://doi.org/10.1016/s1473-3099(14)70920-xopenalex-snapshot
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
inferredcites →https://doi.org/10.1016/s1473-3099(15)70090-3openalex-snapshot
Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
inferredcites →https://doi.org/10.1016/s2055-6640(20)30696-8openalex-snapshot
Treatment strategies for Middle East respiratory syndrome coronavirus
inferredcites →https://doi.org/10.1038/82191openalex-snapshot
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
inferredcites →https://doi.org/10.1038/cr.2015.113openalex-snapshot
A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
inferredcites →https://doi.org/10.1038/nature12005openalex-snapshot
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
inferredcites →https://doi.org/10.1038/ncomms4067openalex-snapshot
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
inferredcites →https://doi.org/10.1038/nm.3362openalex-snapshot
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
inferredcites →https://doi.org/10.1038/nm1001openalex-snapshot
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
inferredcites →https://doi.org/10.1038/nrd.2015.37openalex-snapshot
Coronaviruses — drug discovery and therapeutic options
inferredcites →https://doi.org/10.1038/srep01686openalex-snapshot
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
inferredcites →https://doi.org/10.1038/srep13133openalex-snapshot
Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27
inferredcites →https://doi.org/10.1056/nejm200307313490519openalex-snapshot
Fatal Aspergillosis in a Patient with SARS Who Was Treated with Corticosteroids
inferredcites →https://doi.org/10.1073/pnas.0403596101openalex-snapshot
Small molecules targeting severe acute respiratory syndrome human coronavirus
inferredcites →https://doi.org/10.1073/pnas.1402074111openalex-snapshot
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution
inferredcites →https://doi.org/10.1073/pnas.1510199112openalex-snapshot
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
inferredcites →https://doi.org/10.1073/pnas.1510830112openalex-snapshot
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
inferredcites →https://doi.org/10.1074/jbc.m116.716100openalex-snapshot
Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
inferredcites →https://doi.org/10.1084/jem.25.4.581openalex-snapshot
A REPORT ON THE SERUM TREATMENT OF TWENTY-SIX CASES OF EPIDEMIC POLIOMYELITIS
inferredcites →https://doi.org/10.1086/378304openalex-snapshot
Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada
inferredcites →https://doi.org/10.1086/382597openalex-snapshot
Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferon‐α
inferredcites →https://doi.org/10.1086/424016openalex-snapshot
Factors Associated with Psychosis among Patients with Severe Acute Respiratory Syndrome: A Case-Control Study
inferredcites →https://doi.org/10.1086/429631openalex-snapshot
Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection
inferredcites →https://doi.org/10.1086/514298openalex-snapshot
Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients
inferredcites →https://doi.org/10.1093/cid/ciq106openalex-snapshot
Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection
inferredcites →https://doi.org/10.1093/cid/ciu635openalex-snapshot
Clinical and Laboratory Findings of the First Imported Case of Middle East Respiratory Syndrome Coronavirus to the United States
inferredcites →https://doi.org/10.1093/infdis/jit504openalex-snapshot
Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis
inferredcites →https://doi.org/10.1093/infdis/jit589openalex-snapshot
Investigation of Anti-Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012
inferredcites →https://doi.org/10.1093/infdis/jiu396openalex-snapshot
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
inferredcites →https://doi.org/10.1093/infdis/jiv325openalex-snapshot
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
inferredcites →https://doi.org/10.1093/infdis/jiv392openalex-snapshot
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
inferredcites →https://doi.org/10.1093/jac/dki346openalex-snapshot
Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital
inferredcites →https://doi.org/10.1093/jac/dkv085openalex-snapshot
IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
inferredcites →https://doi.org/10.1097/ftd.0b013e31822d578bopenalex-snapshot
Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
inferredcites →https://doi.org/10.1097/mcp.0000000000000046openalex-snapshot
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome
inferredcites →https://doi.org/10.1099/jmm.0.05320-0openalex-snapshot
Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
inferredcites →https://doi.org/10.1099/vir.0.034983-0openalex-snapshot
Cyclosporin A inhibits the replication of diverse coronaviruses
inferredcites →https://doi.org/10.1099/vir.0.052910-0openalex-snapshot
MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment
inferredcites →https://doi.org/10.1099/vir.0.055533-0openalex-snapshot
Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
inferredcites →https://doi.org/10.1099/vir.0.061911-0openalex-snapshot
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
inferredcites →https://doi.org/10.1111/j.1365-2249.2003.02391.xopenalex-snapshot
Prolonged disturbances ofin vitrocytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids
inferredcites →https://doi.org/10.1111/j.1469-0691.2004.00956.xopenalex-snapshot
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
inferredcites →https://doi.org/10.1111/j.1600-065x.1993.tb00652.xopenalex-snapshot
Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil
inferredcites →https://doi.org/10.1126/scitranslmed.3008140openalex-snapshot
Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein
inferredcites →https://doi.org/10.1126/scitranslmed.aaf1061openalex-snapshot
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
inferredcites →https://doi.org/10.1128/aac.03011-14openalex-snapshot
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
inferredcites →https://doi.org/10.1128/aac.03036-14openalex-snapshot
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
inferredcites →https://doi.org/10.1128/aac.44.4.859-866.2000openalex-snapshot
Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon
inferredcites →https://doi.org/10.1128/jvi.00009-13openalex-snapshot
Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures
inferredcites →https://doi.org/10.1128/jvi.00433-14openalex-snapshot
A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein
inferredcites →https://doi.org/10.1128/jvi.00446-15openalex-snapshot
Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection
inferredcites →https://doi.org/10.1128/jvi.00554-10openalex-snapshot
A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms
inferredcites →https://doi.org/10.1128/jvi.00912-14openalex-snapshot
Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies
inferredcites →https://doi.org/10.1128/jvi.01277-13openalex-snapshot
The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
inferredcites →https://doi.org/10.1128/jvi.01890-13openalex-snapshot
Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2
inferredcites →https://doi.org/10.1128/jvi.02190-07openalex-snapshot
Cytokine Responses in Porcine Respiratory Coronavirus-Infected Pigs Treated with Corticosteroids as a Model for Severe Acute Respiratory Syndrome
inferredcites →https://doi.org/10.1128/jvi.02448-13openalex-snapshot
Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
inferredcites →https://doi.org/10.1128/jvi.02614-07openalex-snapshot
Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro
inferredcites →https://doi.org/10.1128/jvi.03496-12openalex-snapshot
Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus
inferredcites →https://doi.org/10.1128/jvi.06791-11openalex-snapshot
Primary Severe Acute Respiratory Syndrome Coronavirus Infection Limits Replication but Not Lung Inflammation upon Homologous Rechallenge
inferredcites →https://doi.org/10.1128/jvi.78.22.12672-12676.2004openalex-snapshot
Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets
inferredcites →https://doi.org/10.1128/mbio.00165-13openalex-snapshot
Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus
inferredcites →https://doi.org/10.1128/mbio.00611-12openalex-snapshot
Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential
inferredcites →https://doi.org/10.1136/thorax.2003.012658openalex-snapshot
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
inferredcites →https://doi.org/10.1136/thx.2003.014076openalex-snapshot
Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak
inferredcites →https://doi.org/10.1148/radiol.2292030737openalex-snapshot
Severe Acute Respiratory Syndrome: Radiographic Evaluation and Clinical Outcome Measures
inferredcites →https://doi.org/10.1148/radiol.2351040100openalex-snapshot
Osteonecrosis of Hip and Knee in Patients with Severe Acute Respiratory Syndrome Treated with Steroids
inferredcites →https://doi.org/10.1164/rccm.200306-766ocopenalex-snapshot
High–Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome
inferredcites →https://doi.org/10.1164/rccm.201101-0110ocopenalex-snapshot
Corticosteroid Treatment in Critically Ill Patients with Pandemic Influenza A/H1N1 2009 Infection: Analytic Strategy Using Propensity Scores
inferredcites →https://doi.org/10.1164/rccm.201312-2235ocopenalex-snapshot
The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
inferredcites →https://doi.org/10.1177/095632020601700505openalex-snapshot
Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice
inferredcites →https://doi.org/10.1177/135965350400900618openalex-snapshot
Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons
inferredcites →https://doi.org/10.1182/blood-2006-05-023770openalex-snapshot
Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon
inferredcites →https://doi.org/10.1186/1743-422x-10-359openalex-snapshot
In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection
inferredcites →https://doi.org/10.1186/1743-422x-2-69openalex-snapshot
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
inferredcites →https://doi.org/10.1186/1743-422x-3-39openalex-snapshot
In vitro inhibition of human influenza A virus replication by chloroquine.
inferredcites →https://doi.org/10.1186/cc13819openalex-snapshot
Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1186/s12879-016-1492-4openalex-snapshot
Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
inferredcites →https://doi.org/10.1186/s40064-015-1490-9openalex-snapshot
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
inferredcites →https://doi.org/10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8openalex-snapshot
State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans
inferredcites →https://doi.org/10.1371/journal.pmed.0030343openalex-snapshot
SARS: Systematic Review of Treatment Effects
inferredcites →https://doi.org/10.1371/journal.pone.0081587openalex-snapshot
A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
inferredcites →https://doi.org/10.1371/journal.pone.0088716openalex-snapshot
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
inferredcites →https://doi.org/10.1378/chest.12-2907openalex-snapshot
Hyperimmune IV Immunoglobulin Treatment
inferredcites →https://doi.org/10.1517/14656566.2.8.1317openalex-snapshot
Ribavirin - current status of a broad spectrum antiviral agent
inferredcites →https://doi.org/10.2105/ajph.8.10.741openalex-snapshot
THE USE OF CONVALESCENT HUMAN SERUM IN INFLUENZA PNEUMONIA—A PRELIMINARY REPORT
inferredcites →https://doi.org/10.2807/1560-7917.es.2017.22.33.30598openalex-snapshot
Imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection from Oman to Thailand, June 2015
inferredcites →https://doi.org/10.3201/eid1002.030482openalex-snapshot
Interferon-β 1a and SARS Coronavirus Replication
inferredcites →https://doi.org/10.3201/eid1004.030458openalex-snapshot
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
inferredcites →https://doi.org/10.3201/eid1005.030640openalex-snapshot
Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients
inferredcites →https://doi.org/10.3201/eid1912.130701openalex-snapshot
Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia
inferredcites →https://doi.org/10.3201/eid2203.151049openalex-snapshot
Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013
inferredcites →https://doi.org/10.3760/cma.j.issn.0254-6450.2016.02.028openalex-snapshot
[Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV].
inferredcites →https://doi.org/10.3851/imp2792openalex-snapshot
Ribavirin and Interferon-α2b as Primary and Preventive Treatment for Middle East Respiratory Syndrome Coronavirus: A Preliminary Report of Two Cases
inferredcites →https://doi.org/10.3851/imp3002openalex-snapshot
Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome
inferredcites →https://doi.org/10.3947/ic.2015.47.3.212openalex-snapshot
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome
inferredcites →https://doi.org/10.3978/j.issn.2305-5839.2015.01.15openalex-snapshot
Towards the prophylactic and therapeutic use of human neutralizing monoclonal antibodies for Middle East respiratory syndrome coronavirus (MERS-CoV).
inferredcites →https://doi.org/10.4187/respcare.04325openalex-snapshot
Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS
inferredcites →https://doi.org/10.5144/0256-4947.2014.396openalex-snapshot
Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
inferredcites →https://doi.org/10.6118/jmm.2015.21.2.63openalex-snapshot
Considerations Left behind Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Outbreaks in Republic of Korea
inferredcites →https://doi.org/10.7326/m13-2486openalex-snapshot
Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection
inferredcites →https://doi.org/10.7490/f1000research.1112365.1openalex-snapshot
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) response to the Zika virus outbreak

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.3897/pharmacia.72.e159772zenodo-depositor-declared
Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review
inferred← citeshttps://doi.org/10.1002/9781683670438.mcm0093openalex-snapshot
Coronaviruses
inferred← citeshttps://doi.org/10.1002/9781683674849.mcm0093openalex-snapshot
Coronaviruses
inferred← citeshttps://doi.org/10.1002/jcla.23923openalex-snapshot
Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus‐2 infection
inferred← citeshttps://doi.org/10.1002/jmv.25798openalex-snapshot
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
inferred← citeshttps://doi.org/10.1002/jmv.25965openalex-snapshot
The management of coronavirus disease 2019 (COVID‐19)
inferred← citeshttps://doi.org/10.1002/jmv.26470openalex-snapshot
Management of SARS‐CoV‐2 pneumonia
inferred← citeshttps://doi.org/10.1002/jmv.26727openalex-snapshot
Administration of intravenous immunoglobulin in the treatment of COVID‐19: A review of available evidence
inferred← citeshttps://doi.org/10.1007/82_2024_281openalex-snapshot
The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma
inferred← citeshttps://doi.org/10.1007/978-1-0716-0900-2_1openalex-snapshot
Coronaviruses: An Updated Overview of Their Replication and Pathogenesis
inferred← citeshttps://doi.org/10.1007/978-3-662-67508-3_15openalex-snapshot
Orthomolekulare Therapieoptionen mit Mikronährstoffen bei viralen Atemwegserkrankungen
inferred← citeshttps://doi.org/10.1007/s00705-020-04768-3openalex-snapshot
Potential strategies for combating COVID-19
inferred← citeshttps://doi.org/10.1007/s11192-021-04036-4openalex-snapshot
Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature
inferred← citeshttps://doi.org/10.1007/s40138-018-0162-9openalex-snapshot
Emerging Infectious Diseases: a Review
inferred← citeshttps://doi.org/10.1007/s40495-020-00218-5openalex-snapshot
COVID-19 Drug Treatment in China
inferred← citeshttps://doi.org/10.1007/s43440-020-00204-0openalex-snapshot
SARS-CoV-2 therapeutics: how far do we stand from a remedy?
inferred← citeshttps://doi.org/10.1007/s43440-021-00225-3openalex-snapshot
Perspectives on glucocorticoid treatment for COVID-19: a systematic review
inferred← citeshttps://doi.org/10.1016/b978-0-323-99967-0.00197-6openalex-snapshot
Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS)
inferred← citeshttps://doi.org/10.1016/j.antiviral.2018.01.002openalex-snapshot
The role of adjuvant immunomodulatory agents for treatment of severe influenza
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113107openalex-snapshot
Immune-based therapeutic approaches in COVID-19
inferred← citeshttps://doi.org/10.1016/j.cmi.2020.04.031openalex-snapshot
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
inferred← citeshttps://doi.org/10.1016/j.cpha.2023.03.002openalex-snapshot
Severe Acute Respiratory Syndrome Associated Infections
inferred← citeshttps://doi.org/10.1016/j.cyto.2021.155523openalex-snapshot
Aberrant cytokine expression in COVID-19 patients: Associations between cytokines and disease severity
inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2020.105938openalex-snapshot
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.12.014openalex-snapshot
Dynamic anti-spike protein antibody profiles in COVID-19 patients
inferred← citeshttps://doi.org/10.1016/j.intimp.2020.107245openalex-snapshot
Interferon-inducer antivirals: Potential candidates to combat COVID-19
inferred← citeshttps://doi.org/10.1016/j.intimp.2020.107364openalex-snapshot
Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110485openalex-snapshot
Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19
inferred← citeshttps://doi.org/10.1016/j.jiac.2017.04.004openalex-snapshot
Atypical presentations of MERS-CoV infection in immunocompromised hosts
inferred← citeshttps://doi.org/10.1016/j.jinf.2020.03.002openalex-snapshot
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.jiph.2020.10.012openalex-snapshot
Combating COVID-19: The role of drug repurposing and medicinal plants
inferred← citeshttps://doi.org/10.1016/j.jogoh.2020.101846openalex-snapshot
SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development
inferred← citeshttps://doi.org/10.1016/j.lfs.2020.117765openalex-snapshot
The current understanding and potential therapeutic options to combat COVID-19
inferred← citeshttps://doi.org/10.1016/j.medmal.2019.10.004openalex-snapshot
Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)
inferred← citeshttps://doi.org/10.1016/j.mehy.2022.110943openalex-snapshot
COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies
inferred← citeshttps://doi.org/10.1016/j.molstruc.2021.130457openalex-snapshot
Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins
inferred← citeshttps://doi.org/10.1016/j.virusres.2017.01.023openalex-snapshot
Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes
inferred← citeshttps://doi.org/10.1021/acsami.9b15032openalex-snapshot
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
inferred← citeshttps://doi.org/10.1042/bsr20181059openalex-snapshot
Overexpression of the nucleocapsid protein of Middle East respiratory syndrome coronavirus up-regulates CXCL10
inferred← citeshttps://doi.org/10.1080/03602532.2020.1770782openalex-snapshot
The broad-spectrum antiviral recommendations for drug discovery against COVID-19
inferred← citeshttps://doi.org/10.1080/07391102.2023.2283780openalex-snapshot
Identification of synthetically tractable MERS-CoV main protease inhibitors using structure-based virtual screening and molecular dynamics potential of mean force (PMF) calculations
inferred← citeshttps://doi.org/10.1080/13880209.2023.2253841openalex-snapshot
Extracts of Thesium chinense inhibit SARS-CoV-2 and inflammation in vitro
inferred← citeshttps://doi.org/10.1080/14656566.2020.1790526openalex-snapshot
Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19
inferred← citeshttps://doi.org/10.1080/1744666x.2021.1847640openalex-snapshot
Natural history of COVID-19 and therapeutic options
inferred← citeshttps://doi.org/10.1093/infdis/jix264openalex-snapshot
Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution
inferred← citeshttps://doi.org/10.1097/jcma.0000000000000270openalex-snapshot
The outbreak of COVID-19: An overview
inferred← citeshttps://doi.org/10.1099/jgv.0.000919openalex-snapshot
Transgene expression in the genome of Middle East respiratory syndrome coronavirus based on a novel reverse genetics system utilizing Red-mediated recombination cloning
inferred← citeshttps://doi.org/10.1099/jmm.0.000565openalex-snapshot
A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
inferred← citeshttps://doi.org/10.1111/eci.13209openalex-snapshot
The novel Chinese coronavirus (2019‐nCoV) infections: Challenges for fighting the storm
inferred← citeshttps://doi.org/10.1111/tri.13662openalex-snapshot
COVID‐19 in solid organ transplant recipients: a single‐center experience
inferred← citeshttps://doi.org/10.1111/voxs.12581openalex-snapshot
Current status and practical considerations in the development of convalescent plasma as a treatment for COVID‐19
inferred← citeshttps://doi.org/10.1136/jim-2018-000712openalex-snapshot
Viral Pneumonia: Etiologies and Treatment
inferred← citeshttps://doi.org/10.1139/bcb-2020-0341openalex-snapshot
A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis
inferred← citeshttps://doi.org/10.1139/cjpp-2020-0286openalex-snapshot
Current therapies under investigation for COVID-19: potential COVID-19 treatments
inferred← citeshttps://doi.org/10.1159/000486451openalex-snapshot
Pulmonary Diseases in Refugees and Migrants in Europe
inferred← citeshttps://doi.org/10.1159/000522336openalex-snapshot
Latest Insights on the Diagnostic Approaches and Treatment Strategies of COVID-19
inferred← citeshttps://doi.org/10.1177/1753466620926853openalex-snapshot
Potential specific therapies in COVID-19
inferred← citeshttps://doi.org/10.1186/s12879-019-4555-5openalex-snapshot
Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection
inferred← citeshttps://doi.org/10.1186/s12941-020-00414-7openalex-snapshot
MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges
inferred← citeshttps://doi.org/10.1186/s12992-017-0233-9openalex-snapshot
Global research trends of World Health Organization’s top eight emerging pathogens
inferred← citeshttps://doi.org/10.1186/s13063-017-2427-0openalex-snapshot
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
inferred← citeshttps://doi.org/10.12701/yujm.2020.00633openalex-snapshot
Novel respiratory infectious diseases in Korea
inferred← citeshttps://doi.org/10.12998/wjcc.v9.i19.5135openalex-snapshot
Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages
inferred← citeshttps://doi.org/10.15361/2175-0106.2020v36n2p59-71openalex-snapshot
CORONAVIRUSES: THERE AND BACK AGAIN
inferred← citeshttps://doi.org/10.17816/brmma63654openalex-snapshot
Features of immunopathogenesis of a new coronavirus infection
inferred← citeshttps://doi.org/10.18597/rcog.3621openalex-snapshot
Tribulaciones de la investigación en los tiempos de covid-19
inferred← citeshttps://doi.org/10.21203/rs.3.rs-19507/v1openalex-snapshot
Therapeutic Preferences for Coronavirus 2(SARS-CoV-2) Patients
inferred← citeshttps://doi.org/10.21307/pm-2020.59.3.15openalex-snapshot
Covid-19 Therapy: What Have We Learned In 8 Months?
inferred← citeshttps://doi.org/10.21518/2079-701x-2021-16-60-77openalex-snapshot
Viral pneumonia: a new look at an old problem (review)
inferred← citeshttps://doi.org/10.2174/1389450121666200617133142openalex-snapshot
Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19
inferred← citeshttps://doi.org/10.2217/fvl-2018-0016openalex-snapshot
Antiviral Therapeutic Approaches for Human Rhinovirus Infections
inferred← citeshttps://doi.org/10.22271/27069567.2021.v3.i2e.254openalex-snapshot
Synergistic effect of remdesivir and pegylated interferon alfa 1 beta in treatment of Covid 19
inferred← citeshttps://doi.org/10.22541/au.158679942.29108396openalex-snapshot
Efficacies of repurposing chloroquine analogues for the treatment of COVID-19: Facts and myths
inferred← citeshttps://doi.org/10.31788/rjc.2023.1638231openalex-snapshot
PATHOPHYSIOLOGY, RISK ASSESSMENT, AND MANAGEMENT FOR ASTHMA PATIENTS DURING THE COVID-19 PANDEMIC OUTBREAK
inferred← citeshttps://doi.org/10.3332/ecancer.2020.1022openalex-snapshot
Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
inferred← citeshttps://doi.org/10.3389/fimmu.2020.595739openalex-snapshot
The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
inferred← citeshttps://doi.org/10.3389/fmed.2020.581521openalex-snapshot
Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks
inferred← citeshttps://doi.org/10.3389/fmed.2021.808608openalex-snapshot
COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases
inferred← citeshttps://doi.org/10.3389/fmicb.2019.01327openalex-snapshot
Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections
inferred← citeshttps://doi.org/10.3389/fmicb.2020.00658openalex-snapshot
The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses
inferred← citeshttps://doi.org/10.3389/fonc.2021.711225openalex-snapshot
A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds
inferred← citeshttps://doi.org/10.3389/fphar.2020.582025openalex-snapshot
Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines
inferred← citeshttps://doi.org/10.3389/fphar.2021.732403openalex-snapshot
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment
inferred← citeshttps://doi.org/10.3390/biomedicines13030553openalex-snapshot
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients
inferred← citeshttps://doi.org/10.3390/life10080146openalex-snapshot
A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review
inferred← citeshttps://doi.org/10.3390/nano10061072openalex-snapshot
Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses
inferred← citeshttps://doi.org/10.3390/v9120369openalex-snapshot
An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus
inferred← citeshttps://doi.org/10.36468/pharmaceutical-sciences.1033openalex-snapshot
An Overview of the Approaches for the Pharmacotherapy of Pandemic Causing Coronaviruses of the 21st Century
inferred← citeshttps://doi.org/10.3889/oamjms.2020.4854openalex-snapshot
Potential Antiviral Effect of Chloroquine Therapy against SARS-CoV-2 Infection
inferred← citeshttps://doi.org/10.3947/ic.2020.52.1.105openalex-snapshot
Emergent Strategies for the Next Phase of COVID-19
inferred← citeshttps://doi.org/10.3947/ic.2021.0303openalex-snapshot
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
inferred← citeshttps://doi.org/10.4103/ijot.ijot_137_20openalex-snapshot
Clinical Characteristics and Outcome of Novel Coronavirus Disease in Kidney Transplant Recipients
inferred← citeshttps://doi.org/10.4236/ojrm.2020.92006openalex-snapshot
COVID-19 Pandemic: Its Origin, Implications and Treatments
inferred← citeshttps://doi.org/10.47262/bl/12.1.20230220openalex-snapshot
The COVID-19 pandemic: A comprehensive biomedical review of its impact on healthcare, employment, and academic sectors
inferred← citeshttps://doi.org/10.48107/cmj.2020.05.006openalex-snapshot
A literature review of drugs for the treatment of COVID-19
inferred← citeshttps://doi.org/10.48550/arxiv.2106.04810openalex-snapshot
Sleeping beauties and temporal evolution of the coronavirus literature
inferred← citeshttps://doi.org/10.5694/mja2.50577openalex-snapshot
Corticosteroid treatment of patients with coronavirus disease 2019 ( COVID ‐19)
inferred← citeshttps://doi.org/10.70675/7177b7efz0f27z4bdaz9ae2zfd5cc05a8100openalex-snapshot
Carbon nanomaterials as antibacterial and antiviral alternatives
inferred← citeshttps://doi.org/10.7189/jogh.11.10003openalex-snapshot
Current COVID-19 treatments: Rapid review of the literature
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.